In vitro pharmacologic profiling aids systemic toxicity assessment of chemicals.

Autor: Burbank M; L'Oréal Research & Innovation, Aulnay-Sous-Bois, France. Electronic address: matthew.burbank@loreal.com., Kukic P; Unilever Safety and Environmental Assurance Centre, Bedfordshire, MK 44 1LQ, UK., Ouedraogo G; L'Oréal Research & Innovation, Aulnay-Sous-Bois, France., Kenna JG; Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160 Brussels, Belgium., Hewitt NJ; Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160 Brussels, Belgium., Armstrong D; Armstrong Pharmacology Ltd, Macclesfield, UK., Otto-Bruc A; Eurofins Cerep, Celle-Lévescault, France., Ebmeyer J; Beiersdorf AG; Beiersdorfstraße 1-9, 20245 Hamburg, Germany., Boettcher M; Beiersdorf AG; Beiersdorfstraße 1-9, 20245 Hamburg, Germany., Willox I; Eurofins Cerep, Celle-Lévescault, France., Mahony C; Procter & Gamble Technical Centres Ltd, Reading, UK.

Publikováno v: Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2024 Nov; Vol. 492, pp. 117131. Date of Electronic Publication: 2024 Oct 20.

Corrigendum to Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment.

Autor: Turner J; Safer Medicines Trust, Kingsbridge, UK., Pound P; Safer Medicines Trust, Kingsbridge, UK., Owen C; Animal Free Research UK, London, UK., Hutchinson I; Animal Free Research UK, London, UK., Hop M; Viveo Consulting Ltd, London, UK., Chau DYS; Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, London, UK., Barrios Silva LV; Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, London, UK., Coleman M; College of Health and Life Sciences, Aston University, Birmingham, UK., Dubourg A; CN Bio Innovations Limited, Cambridge, UK., Harries LW; University of Exeter Medical School, Exeter, UK., Hutter V; ImmuONE Limited, Hatfield, UK; Centre for Topical Drug Delivery and Toxicology, University of Hertfordshire, Hatfield, UK., Kenna JG; Safer Medicines Trust, Kingsbridge, UK., Lauschke VM; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany., Neuhaus W; Austrian Institute of Technology GmbH, Competence Unit Molecular Diagnostics, Vienna, Austria; Department of Medicine, Danube Private University, Krems, Austria., Roper C; Roper Toxicology Consulting Limited, Edinburgh, UK., Watkins PB; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA., Welch J; Newcells Biotech, Newcastle upon Tyne, UK., Rego Avarez L; Cruelty Free International, London, UK., Taylor K; Cruelty Free International, London, UK.

Publikováno v: ALTEX [ALTEX] 2024; Vol. 41 (4), pp. 674-675.

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats.

Autor: Melillo N; Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Science, The University of Manchester, Manchester M13 9PL, UK.; SystemsForecastingUK Ltd., Lancaster LA1 5DD, UK., Scotcher D; Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Science, The University of Manchester, Manchester M13 9PL, UK., Kenna JG; Bioxydyn Ltd., Manchester M15 6SZ, UK., Green C; MR & CT Contrast Media Research, Bayer AG, 13353 Berlin, Germany., Hines CDG; GSK, Collegeville, PA 19426, USA., Laitinen I; Sanofi-Aventis Deutschland GmbH, Bioimaging Germany, 65929 Frankfurt am Main, Germany.; Antaros Medical, 431 83 Mölndal, Sweden., Hockings PD; Antaros Medical, 431 83 Mölndal, Sweden.; MedTech West, Chalmers University of Technology, 413 45 Gothenburg, Sweden., Ogungbenro K; Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Science, The University of Manchester, Manchester M13 9PL, UK., Gunwhy ER; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2TA, UK., Sourbron S; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2TA, UK., Waterton JC; Bioxydyn Ltd., Manchester M15 6SZ, UK.; Centre for Imaging Sciences, Division of Informatics Imaging & Data Sciences, School of Health Sciences, The University of Manchester, Manchester M13 9PL, UK., Schuetz G; MR & CT Contrast Media Research, Bayer AG, 13353 Berlin, Germany., Galetin A; Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Science, The University of Manchester, Manchester M13 9PL, UK.

Publikováno v: Pharmaceutics [Pharmaceutics] 2023 Mar 10; Vol. 15 (3). Date of Electronic Publication: 2023 Mar 10.

MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF2.

Autor: Han, Xiao^1,2,3 (AUTHOR), Zhang, Yupeng³ (AUTHOR), Li, Yin³ (AUTHOR), Lin, Zhoujun³ (AUTHOR), Fu, Zhenkun⁴ (AUTHOR), Wang, Changjun⁵ (AUTHOR) wcj_sumy@126.com, Zhang, Shengjie^1,2 (AUTHOR) zhangsj@zjcc.org.cn, Shao, Di^6,7 (AUTHOR) di.shao@cgghcc.com, Li, Chenggang³ (AUTHOR) lichenggang@nankai.edu.cn

Publikováno v: Cell Proliferation. Nov2024, Vol. 57 Issue 11, p1-16. 16p.

The Lipoic Acid Containing Components of the 2-Oxoacid Dehydrogenase Complexes Mimic Trifluoroacetylated Proteins and Are Autoantigens Associated with Halothane Hepatitis

Autor: Urs Christen, Gandolfi Aj, Jenö P, Shimomura Y, Josef Gut, Ranek L, Frey N, Kenna Jg, Stephen J. Yeaman

Publikováno v: Chemical Research in Toxicology. 8:736-746

Anti-CF3CO antibodies, monospecific toward trifluoroacetylated proteins (CF3CO-proteins), which are elicited in experimental animals and humans exposed to the anesthetic agent halothane, cross-react with an unknown protein of approximately 52 kDa, co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d7b48d006d51368750834650e67eb8
https://doi.org/10.1021/tx00047a014